Amgen Reduces Drug Prices to Enhance Affordable Healthcare Through Innovative Pricing Models

Amgen's Commitment to Affordable Healthcare Through Innovative Drug Pricing Models

Amgen, the biotechnology giant based in Thousand Oaks, California, reinforces its dedication to affordable healthcare by expanding its innovative AmgenNow™ program. Recently, the company announces significant reductions in the prices of its medications Aimovig® and Amjevita®, bringing them down to $299 per month—representing discounts of nearly 60% and 80% from their current U.S. list prices, respectively. This initiative is part of Amgen’s ongoing commitment to reducing medication costs for American patients, particularly in response to increasing pressures from policymakers to address the soaring prices of prescription drugs. The AmgenNow program, which originally launched in October 2025 with the drug Repatha® priced at $239 monthly, is accessible to all eligible patients, regardless of their insurance status, including those who are uninsured or on high-deductible plans.

Amgen's strategic move to lower drug prices aligns with broader efforts to enhance accessibility to essential medications for American consumers. This approach comes at a time when healthcare affordability remains a pressing issue, particularly for vulnerable populations relying on public programs like Medicaid. The company's expansion of AmgenNow demonstrates a proactive stance in the healthcare landscape, allowing millions of patients to access life-saving treatments without the burden of exorbitant costs. By leveraging its expertise in biotechnology and commitment to innovation, Amgen seeks to address long-standing concerns regarding drug pricing while simultaneously fostering a competitive marketplace for pharmaceuticals.

In addition to its pricing initiatives, Amgen highlights its significant investments in U.S. manufacturing and research and development, totaling over $40 billion since 2018. This commitment is furthered by an additional $2.5 billion capital investment announced this year, focused on expanding facilities in states like Ohio and North Carolina. Such investments not only bolster Amgen’s production capabilities but also support the U.S. economy and ensure a stable supply of medications. By navigating beneficial tax policies and collaborating with government initiatives, Amgen positions itself as a leader in the biotechnology sector, dedicated to innovation and patient access.

In conjunction with Amgen's initiatives, the broader pharmaceutical industry is responding to the urgent need for price reductions in prescription medications. Recently, President Trump announces agreements with nine major pharmaceutical companies, including Amgen, which commit a total of $150 billion towards domestic manufacturing and research efforts. These agreements aim to enhance affordability for cash payers and Medicaid recipients, signifying a concerted effort to align U.S. drug prices with those in other affluent nations. Through these collaborative efforts, the healthcare landscape may experience transformative changes that benefit millions of Americans grappling with high medication costs. As the nation anticipates the launch of resources like TrumpRX.gov in early 2026, the hope is that greater access to affordable medications will become a reality for many.